Effects of tetracycline on myocardial infarct size in obese rats with chemically-induced colitis

Borshchev, Yury; Минасян, С. М.; Burovenko, I. Yu.; Borshchev, V. Yu.; Protsak, E. S.; Semenova, N. Yu.; Borshcheva, O. V.; Galagudza, M. M.

doi:10.1371/journal.pone.0225185

Cited by 10 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Histopathological changes in mice heart were determined by Hematoxylin and Eosin (H & E) staining. Briefly, tissue samples were fixed in formalin and processed for H & E staining as per the standard laboratory protocol [ 16 ]. The stained tissue sections were examined under light microscope (Lx 300, Labomed, USA).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity

Tambe

Aranjani

Bharati

2023

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose The mitochondria-targeted antioxidants (MTAs) are known to offer protection against mitochondrial oxidative stress. The recent evidences support their role in mitigating oxidative stress-induced diseases, including cancer. Therefore, this study investigated cardioprotective potential of mito-TEMPO against 5-FU-induced cardiotoxicity. Methods Mito-TEMPO was administered to male BALB/C mice (intraperitoneally, 0.1 mg/kg b.w. for 7 days) followed by intraperitoneal administration of 5- FU (12 mg/kg b.w. for 4 days). During this period, mito-TEMPO treatment was also continued. The cardioprotective potential of mito-TEMPO was assessed by evaluating cardiac injury markers, extent of non-viable myocardium and histopathological alterations. Mitochondrial functional status and mitochondrial oxidative stress were assessed in cardiac tissue. 8-OHdG expression and apoptotic cell death were assessed using immunohistochemical techniques. Results The level of cardiac injury markers CK-MB and AST were significantly (P ≤ 0.05) decreased in mito-TEMPO pre-protected group which was further reflected in histopathology as decrease in the percentage of non-viable myocardial tissue, disorganization, and loss of myofibrils. Mito-TEMPO ameliorated mtROS, mtLPO and conserved mitochondrial membrane potential. Further, it had significantly (P ≤ 0.05) improved the activity of mitochondrial complexes and mitochondrial enzymes. A significant (P ≤ 0.05) increase in the level of mtGSH, activity of mitochondrial glutathione reductase, glutathione peroxidase, and mitochondrial superoxide dismutase was observed. A decreased expression of 8-OHdG and reduced apoptotic cell death were observed in mito-TEMPO pre-protected group. Conclusion Mito-TEMPO effectively mitigated 5-FU-induced cardiotoxicity by modulating mitochondrial oxidative stress, hence may serve as a protective agent/adjuvant in 5-FU-based combinatorial chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Non-viable myocardial tissue was assessed by 2,3,5-triphenyltetrazolium chloride (TTC) staining of heart tissue [ 16 ]. Briefly, excised heart tissues were washed with ice-cold 0.9% normal saline and thin transverse sections of the tissue were obtained.…”

Section: Methodsmentioning

confidence: 99%

Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity

Tambe

Aranjani

Bharati

2023

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Previously, studies have reported a low gut abundance of bifidobacteria in rats 148 and humans 149 with MI. However, they did not conclusively determine whether bifidobacteria are cardioprotective against MI.…”

Section: Current Applications In Cardiovascular Diseasementioning

confidence: 98%

The therapeutic value of bifidobacteria in cardiovascular disease

Tang,

Wei,

et al. 2023

npj Biofilms Microbiomes

View full text Add to dashboard Cite

There has been an increase in cardiovascular morbidity and mortality over the past few decades, making cardiovascular disease (CVD) the leading cause of death worldwide. However, the pathogenesis of CVD is multi-factorial, complex, and not fully understood. The gut microbiome has long been recognized to play a critical role in maintaining the physiological and metabolic health of the host. Recent scientific advances have provided evidence that alterations in the gut microbiome and its metabolites have a profound influence on the development and progression of CVD. Among the trillions of microorganisms in the gut, bifidobacteria, which, interestingly, were found through the literature to play a key role not only in regulating gut microbiota function and metabolism, but also in reducing classical risk factors for CVD (e.g., obesity, hyperlipidemia, diabetes) by suppressing oxidative stress, improving immunomodulation, and correcting lipid, glucose, and cholesterol metabolism. This review explores the direct and indirect effects of bifidobacteria on the development of CVD and highlights its potential therapeutic value in hypertension, atherosclerosis, myocardial infarction, and heart failure. By describing the key role of Bifidobacterium in the link between gut microbiology and CVD, we aim to provide a theoretical basis for improving the subsequent clinical applications of Bifidobacterium and for the development of Bifidobacterium nutritional products.

show abstract

“…В литературе практически отсутствуют научно обоснованные данные о влиянии ПП на устойчивость миокарда к ишемическому и реперфузионному повреждению. Нами была показана отмена кардиопротективного эффекта тетрациклина, характерного для здоровых животных, при моделировании полиморбидности [6], что послужило основой для гипотезы о взаимосвязи воспалительного статуса макроорганизма, состава его микробиоты и устойчивости миокарда к ишемии-реперфузии. Общей патогенетической базой таких нарушений, как ожирение, химически индуцированный колит и антибиотик-индуцированный дисбиоз (АИД), является системный воспалительный ответ с большей или меньшей степенью интенсивности увеличения концентрации в крови таких провоспалительных цитокинов, как IL-1, IL-6, IL-18, IFNγ и TNFα.…”

Section: Introductionunclassified

Effects of <i>Lactobacillus delbrueckii</i> TS1-06 probiotic strain on the size of myocardial infarction in Wistar rats with systemic inflammatory response syndrome

Borshchev,

Minasian,

Karaseva

et al. 2023

Med. immunol.

Self Cite

View full text Add to dashboard Cite

Experimental medicine provides the scientific community with a plethora of information on therapeutic efficacy of probiotic strains. However, from the point of view of evidence-based medicine, the list of disorders controlled by probiotics is limited to antibiotic-associated diarrhea in adults and children, Clostridium difficile-associated diarrhea, acute infectious diarrhea in children and adults, eradication therapy, ulcerative colitis and irritable bowel syndrome. Recently, these indications are also amended by well-validated clinical guidelines for the usage of probiotic preparations, in order to modulate immunity. Given the permeability of gastrointestinal and immune system barriers for pathogenic and opportunistic microbiota, it seems logical to assume the effectiveness of probiotics as potential symbiotic regulators of nervous and cardiovascular systems. It should also be taken into account that metabolic disorders, e.g., obesity, with a low-intensity inflammatory response and characteristic cytokine pattern, are acquired as a gain of human civilization. In this regard, we propose a scientific hypothesis about the effectiveness of probiotic microbial strains in increasing myocardial resistance to ischemic-reperfusion injury, due to their ability to block individual links of the cytokine cascade during the development of inflammatory response, for its subsequent translation into clinical practice.The development and validation of a new experimental model of systemic inflammatory response syndrome (SIRS) in male Wistar rats, including obesity, acute inflammatory process of the colon, and antibiotic-induced dysbiosis, became basic to the study of efficacy of probiotic drugs in terms of myocardial resistance to ischemicreperfusion injury (IRI). Rats with SIRS showed a significantly increased size of the infarction area (+28%) upon experiments with isolated perfused heart under global ischemia-reperfusion conditions. Significant changes in the leukocyte formula and immunological parameters associated with SIRS were corrected by introduction of a mixture of probiotic strains L. acidophilus (LA-5) and B. animalis subsp. lactis (BB-12), and the isolated strain L. delbrueckii TS1-06. In both groups with probiotic correction, there was a decrease in the infarction area compared to the SIRS group. General and specific changes in IL-2, transforming growth factor-b (TGF-b) and tumor necrosis factor-a (TNFa) were noted. The reduction of myocardial infarction by probiotics may be related to the blocking of first-order cytokines, which leads to a «break» of proinflammatory cascade. A need for in-depth study of cardioprotective mechanisms mediated by probiotics was confirmed due to their potential usage as a symbiotic alternative to biological drugs which block the main pro-inflammatory cytokines.

show abstract

Effects of tetracycline on myocardial infarct size in obese rats with chemically-induced colitis

Cited by 10 publications

References 43 publications

Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity

Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity

The therapeutic value of bifidobacteria in cardiovascular disease

Effects of <i>Lactobacillus delbrueckii</i> TS1-06 probiotic strain on the size of myocardial infarction in Wistar rats with systemic inflammatory response syndrome

Contact Info

Product

Resources

About